Fintel reports that on February 9, 2026, Barrington Research initiated coverage of Bioventus (NasdaqGS:BVS) with a Outperform recommendation.
Analyst Price Forecast Suggests 79.79% Upside
As of February 4, 2026, the average one-year price target for Bioventus is $15.30/share. The forecasts range from a low of $15.15 to a high of $15.75. The average price target represents an increase of 79.79% from its latest reported closing price of $8.51 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Bioventus is 647MM, an increase of 14.83%. The projected annual non-GAAP EPS is 1.66.
What is the Fund Sentiment?
There are 260 funds or institutions reporting positions in Bioventus. This is an decrease of 54 owner(s) or 17.20% in the last quarter. Average portfolio weight of all funds dedicated to BVS is 0.23%, an increase of 15.39%. Total shares owned by institutions increased in the last three months by 0.08% to 54,236K shares. 
The put/call ratio of BVS is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Essex Woodlands Management holds 13,021K shares representing 19.44% ownership of the company. No change in the last quarter.
Juniper Investment Company holds 6,939K shares representing 10.36% ownership of the company. No change in the last quarter.
Nantahala Capital Management holds 5,811K shares representing 8.68% ownership of the company. In its prior filing, the firm reported owning 5,281K shares , representing an increase of 9.12%. The firm decreased its portfolio allocation in BVS by 1.45% over the last quarter.
Royce & Associates holds 1,251K shares representing 1.87% ownership of the company. In its prior filing, the firm reported owning 1,263K shares , representing a decrease of 0.93%. The firm increased its portfolio allocation in BVS by 12.06% over the last quarter.
IWM – iShares Russell 2000 ETF holds 1,141K shares representing 1.70% ownership of the company. In its prior filing, the firm reported owning 1,027K shares , representing an increase of 10.01%. The firm decreased its portfolio allocation in BVS by 18.83% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
